Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved medicine and 30 medicines in development Quantitative PSMA-PET imaging is required to determine patient eligibility for the first FDA-approved PSMA-targeting medicine and is an inclusion criterion for ongoing trials BOSTON, Sept. 15, 2024 (GLOBE NEWSWIRE) — Precede Biosciences, a […]
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.